Details of the Drug

General Information of Drug (ID: DMRKXPT)

Drug Name

Ketoprofen

Synonyms

Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid

Indication

Disease Entry	ICD 11	Status	REF
Bursitis	N.A.	Approved	[1]
Dysmenorrhea	GA34.3	Approved	[1]
Musculoskeletal pain	MG30	Approved	[2]
Pain	MG30-MG3Z	Phase 3	[3]
Migraine	8A80	Phase 2	[4]
Osteoarthritis	FA00-FA05	Phase 1	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

254.28

Logarithm of the Partition Coefficient (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly and well-absorbed orally []
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.5-2 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [6]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.6 mL/min/kg [7]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 - 4 hours [7]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.66259 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.008% [7]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.13 L/kg [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.18 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Gastrointestinal toxicity	Not Available	TNF	OT4IE164	[9]
Gastrointestinal toxicity	Not Available	GSR	OTM2TUYM	[9]
-----------

Chemical Identifiers

Formula: C16H14O3
IUPAC Name: 2-(3-benzoylphenyl)propanoic acid
Canonical SMILES: CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
InChI: InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey: DKYWVDODHFEZIM-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3825
ChEBI ID: CHEBI:6128
CAS Number: 22071-15-4
DrugBank ID: DB01009
TTD ID: D0W9WF
VARIDT ID: DR00690
INTEDE ID: DR0907
ACDINA ID: D00343

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[13]
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Gene/Protein Processing	[14]
Dehydrogenase/reductase SDR family member 11 (DHRS11)	OTU3J0ZL	DHR11_HUMAN	Gene/Protein Processing	[15]
Glutamate--cysteine ligase catalytic subunit (GCLC)	OTESDI4D	GSH1_HUMAN	Gene/Protein Processing	[16]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Gene/Protein Processing	[16]
Glutathione reductase, mitochondrial (GSR)	OTM2TUYM	GSHR_HUMAN	Drug Response	[9]
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1)	OT7OG7Y2	DPA1_HUMAN	Gene/Protein Processing	[17]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Gene/Protein Processing	[17]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Gene/Protein Processing	[18]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

15 Disease of the musculoskeletal system/connective tissue

Disease Class

ICD-11: FA20 Rheumatoid arthritis

The Studied Tissue

Synovial tissue

The Studied Disease

Osteoarthritis [ICD-11:FA20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	3.32E-01	1.67	0.74
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	4.11E-01	5.03E-03	2.97E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.34E-03	-2.37E-01	-1.13E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ketoprofen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Levomilnacipran.	Chronic pain [MG30]	[20]
-----------

Coadministration of a Drug Treating the Disease Different from Ketoprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[21]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Glibenclamide.	Acute diabete complication [5A2Y]	[22]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Glipizide.	Acute diabete complication [5A2Y]	[22]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Ketoprofen caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Inotersen.	Amyloidosis [5D00]	[23]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[24]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Cilostazol.	Arterial occlusive disease [BD40]	[25]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Budesonide.	Asthma [CA23]	[26]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Kanamycin.	Bacterial infection [1A00-1C4Z]	[28]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Streptomycin.	Bacterial infection [1A00-1C4Z]	[28]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Ketoprofen and ABT-492.	Bacterial infection [1A00-1C4Z]	[27]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Etidronic acid.	Bone paget disease [FB85]	[29]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[30]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Ketoprofen caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[25]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Iodipamide.	Cholelithiasis [DC11]	[32]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Ketoprofen and Regorafenib.	Colorectal cancer [2B91]	[23]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Ketoprofen and Drospirenone.	Contraceptive management [QA21]	[33]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Methoxyflurane.	Corneal disease [9A76-9A78]	[23]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Ketoprofen and Ardeparin.	Coronary thrombosis [BA43]	[34]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Ketoprofen and Danaparoid.	Deep vein thrombosis [BD71]	[34]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Ketoprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[35]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sertraline.	Depression [6A70-6A7Z]	[20]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Vilazodone.	Depression [6A70-6A7Z]	[20]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Vortioxetine.	Depression [6A70-6A7Z]	[20]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Milnacipran.	Depression [6A70-6A7Z]	[20]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Escitalopram.	Depression [6A70-6A7Z]	[20]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Desvenlafaxine.	Depression [6A70-6A7Z]	[20]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Clomipramine.	Depression [6A70-6A7Z]	[20]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Cannabidiol.	Epileptic encephalopathy [8A62]	[23]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Tazemetostat.	Follicular lymphoma [2A80]	[25]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Ketoprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[23]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sulfinpyrazone.	Gout [FA25]	[25]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[36]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[37]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[38]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[39]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Ketoprofen when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[40]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Balsalazide.	Indeterminate colitis [DD72]	[41]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ketoprofen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[21]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[42]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Idelalisib.	Mature B-cell leukaemia [2A82]	[43]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Ketoprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[44]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Ketoprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[45]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Ketoprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[46]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Exjade.	Mineral absorption/transport disorder [5C64]	[47]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Deflazacort.	Muscular dystrophy [8C70]	[26]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Ketoprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[48]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Ketoprofen and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[49]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Ketoprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[23]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Ketoprofen and Vorapaxar.	Myocardial infarction [BA41-BA43]	[50]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Sibutramine.	Obesity [5B80-5B81]	[20]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Dexfenfluramine.	Obesity [5B80-5B81]	[20]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Ketoprofen when combined with Polythiazide.	Oedema [MG29]	[40]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Ketoprofen and MK-4827.	Ovarian cancer [2C73]	[23]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[51]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Iloprost.	Pulmonary hypertension [BB01]	[51]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Everolimus.	Renal cell carcinoma [2C90]	[52]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Ketoprofen and Temsirolimus.	Renal cell carcinoma [2C90]	[52]
Gatifloxacin	DMSL679	Moderate	Additive CNS depression effects by the combination of Ketoprofen and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[27]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Dexamethasone.	Rheumatoid arthritis [FA20]	[26]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Ketoprofen and Leflunomide.	Rheumatoid arthritis [FA20]	[38]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Ketoprofen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[23]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ketoprofen and Pitolisant.	Somnolence [MG42]	[23]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Caplacizumab.	Thrombocytopenia [3B64]	[25]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Ketoprofen and Apixaban.	Thrombosis [DB61-GB90]	[23]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Cangrelor.	Thrombosis [DB61-GB90]	[25]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Ketoprofen and Brilinta.	Thrombosis [DB61-GB90]	[23]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Ketoprofen and Cabozantinib.	Thyroid cancer [2D10]	[53]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Ketoprofen and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[22]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Olsalazine.	Ulcerative colitis [DD71]	[41]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Ketoprofen and Plazomicin.	Urinary tract infection [GC08]	[28]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Ketoprofen and Betrixaban.	Venous thromboembolism [BD72]	[54]
-----------


⏷ Show the Full List of 78 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ketoprofen 200 mg capsule	200 mg	24 HR Extended Release Oral Capsule	Oral
Ketoprofen 50 mg capsule	50 mg	Oral Capsule	Oral
Ketoprofen 75 mg capsule	75 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Ketoprofen FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4795).
3	Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	BDDCS applied to over 900 drugs
6	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
11	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
12	Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
13	A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
14	Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
15	Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
16	Redox-sensitive interaction between KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-glutamylcysteine synthetase. Free Radic Biol Med. 2002 Apr 1;32(7):650-62. doi: 10.1016/s0891-5849(02)00755-4.
17	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
18	Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
19	Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
20	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
21	Cerner Multum, Inc. "Australian Product Information.".
22	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
25	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
26	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
27	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
28	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
29	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
30	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
33	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
34	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
35	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
36	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
37	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
38	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
39	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
40	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
41	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
42	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
43	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
44	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
46	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
47	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
48	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
49	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
50	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
51	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
52	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
53	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
54	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.